Guixue Liu1, Zhihan Xu2, Yaping Zhang1, Beibei Jiang1, Lu Zhang1, Lingyun Wang1, Geertruida H de Bock3, Rozemarijn Vliegenthart4, Xueqian Xie1. 1. Department of Radiology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. 2. DI CT Collaboration, Siemens Healthineers Ltd., Shanghai, China. 3. Department of Epidemiology, Hanzeplein 1, University Medical Center Groningen, University of Groningen, Groningen, Netherlands. 4. Department of Radiology, Hanzeplein 1, University Medical Center Groningen, University of Groningen, Groningen, Netherlands.
Abstract
BACKGROUND: To establish a machine-learning-derived nomogram based on radiomic features and clinical factors to predict post-surgical 2-year progression-free survival (PFS) in patients with lung adenocarcinoma. METHODS: Patients with >2 years post-surgical prognosis results of lung adenocarcinoma were included in Hospital-1 for model training (n = 100) and internal validation (n = 50), and in Hospital-2 for external testing (n = 50). A total of 1,672 radiomic features were extracted from 3D segmented CT images. The Rad-score was established using random survival forest by accumulating and weighting the top-20 imaging features contributive to PFS. A nomogram for predicting PFS was established, which comprised the Rad-score and clinical factors highly relevant to PFS. RESULTS: In the training, internal validation, and external test groups, 69/100 (69%), 37/50 (74%) and 36/50 (72%) patients were progression-free at two years, respectively. According to the Rad-score, the integral of area under the curve (iAUC) for discriminating high and low risk of progression was 0.92 (95%CI: 0.77-1.0), 0.70 (0.41-0.98) and 0.90 (0.65-1.0), respectively. The C-index of Rad-score was 0.781 and 0.860 in the training and external test groups, higher than 0.707 and 0.606 for TNM stage, respectively. The nomogram integrating Rad-score and clinical factors (lung nodule type, cM stage and histological type) achieved a C-index of 0.845 and 0.837 to predict 2-year PFS, respectively, significantly higher than by only radiomic features (all p < 0.01). CONCLUSION: The nomogram comprising CT-derived radiomic features and risk factors showed a high performance in predicting post-surgical 2-year PFS of patients with lung adenocarcinoma, which may help personalize the treatment decisions.
BACKGROUND: To establish a machine-learning-derived nomogram based on radiomic features and clinical factors to predict post-surgical 2-year progression-free survival (PFS) in patients with lung adenocarcinoma. METHODS: Patients with >2 years post-surgical prognosis results of lung adenocarcinoma were included in Hospital-1 for model training (n = 100) and internal validation (n = 50), and in Hospital-2 for external testing (n = 50). A total of 1,672 radiomic features were extracted from 3D segmented CT images. The Rad-score was established using random survival forest by accumulating and weighting the top-20 imaging features contributive to PFS. A nomogram for predicting PFS was established, which comprised the Rad-score and clinical factors highly relevant to PFS. RESULTS: In the training, internal validation, and external test groups, 69/100 (69%), 37/50 (74%) and 36/50 (72%) patients were progression-free at two years, respectively. According to the Rad-score, the integral of area under the curve (iAUC) for discriminating high and low risk of progression was 0.92 (95%CI: 0.77-1.0), 0.70 (0.41-0.98) and 0.90 (0.65-1.0), respectively. The C-index of Rad-score was 0.781 and 0.860 in the training and external test groups, higher than 0.707 and 0.606 for TNM stage, respectively. The nomogram integrating Rad-score and clinical factors (lung nodule type, cM stage and histological type) achieved a C-index of 0.845 and 0.837 to predict 2-year PFS, respectively, significantly higher than by only radiomic features (all p < 0.01). CONCLUSION: The nomogram comprising CT-derived radiomic features and risk factors showed a high performance in predicting post-surgical 2-year PFS of patients with lung adenocarcinoma, which may help personalize the treatment decisions.
Authors: Mohammadhadi Khorrami; Kaustav Bera; Patrick Leo; Pranjal Vaidya; Pradnya Patil; Rajat Thawani; Priya Velu; Prabhakar Rajiah; Mehdi Alilou; Humberto Choi; Michael D Feldman; Robert C Gilkeson; Philip Linden; Pingfu Fu; Harvey Pass; Vamsidhar Velcheti; Anant Madabhushi Journal: Lung Cancer Date: 2020-02-26 Impact factor: 5.705
Authors: Ahmed Hosny; Chintan Parmar; Thibaud P Coroller; Patrick Grossmann; Roman Zeleznik; Avnish Kumar; Johan Bussink; Robert J Gillies; Raymond H Mak; Hugo J W L Aerts Journal: PLoS Med Date: 2018-11-30 Impact factor: 11.069
Authors: Hugo J W L Aerts; Emmanuel Rios Velazquez; Ralph T H Leijenaar; Chintan Parmar; Patrick Grossmann; Sara Carvalho; Sara Cavalho; Johan Bussink; René Monshouwer; Benjamin Haibe-Kains; Derek Rietveld; Frank Hoebers; Michelle M Rietbergen; C René Leemans; Andre Dekker; John Quackenbush; Robert J Gillies; Philippe Lambin Journal: Nat Commun Date: 2014-06-03 Impact factor: 14.919